Vitreoretinal lymphoma (VRL) is often a diffuse large B-cell lymphoma in nature, and patients may have or eventually develop central nervous system lymphoma, which frequently leads to a poor prognosis. Currently, there are no international or domestic clinical guidelines specifically for the diagnosis and treatment of VRL, and no standardized diagnostic procedures or treatment evaluation systems for this disease. VRL is clinically characterized by prominent vitreous opacities, multiple lesions beneath the retinal pigment epithelium or subretinal, and intraretinal infiltration, making it one of the most common masquerade syndromes in ophthalmology. To promote early diagnosis and standardized treatment of VRL, the Ocular Immunology Group of the Chinese Medical Association Ophthalmology Branch has developed "Clinical Guidelines for the Diagnosis and Treatment of Vitreoretinal Lymphoma in Chinese Patients (2024)", based on extensive references to diagnosis, treatment experiences and relevant clinical recommendations. The working group systematically reviewed and comprehensively summarized the latest research evidence from both domestic and international sources. Using the Oxford Evidence Level System, we assessed the quality of evidence and the strength of recommendations. This guideline provides crucial academic references and clinical practice guidance for the diagnosis and treatment of VRL patients. This guideline, including VRL diagnostic methods, processes, and treatment recommendations is suitable for clinical practice in China and is intended to assist ophthalmologists in clinical diagnosis and treatment of VRL.